Pfizer subcutaneous injection of BCMA × CD3 dual antibody is proposed to be included in CDE priority evaluation
芊芊551
发表于 2024-1-31 15:06:31
201
0
0
On January 31st, the official website of the Drug Evaluation Center (CDE) of the National Medical Products Administration announced that Pfizer has submitted an application for the marketing of Elanatamab injection in China and has been accepted. At the same time, the product is also proposed to be included in the CDE's priority review, targeting adult patients with recurrent or refractory multiple myeloma (MM) who have received at least three treatments in the past.
Elanatamab is a subcutaneous injection of BCMA × CD3 bispecific antibody has been approved by the US FDA in August 2023 for the treatment of recurrent/refractory MM patients.
According to publicly available information from Pfizer, elranatamab is a bispecific antibody that targets BCMA and CD3 through subcutaneous injection. One end of the antibody binds to BCMA on myeloma cells, while the other end binds to CD3 receptors on the surface of T cells, causing them to bind together and activate T cells to kill myeloma cells. In addition, elranatamab is used to treat patients through subcutaneous injection, which is more convenient than intravenous injection and may slow down the occurrence of potential side effects such as cytokine release syndrome (CRS).
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- France has received a total investment commitment of 15 billion euros from companies such as Microsoft, Amazon, and Pfizer
- Pfizer Chief Scientist to step down
- Pfizer invests $743 million to expand its Singapore factory
- Pfizer fights cancer business again, plans to expand these territories in China within six years
- Pfizer's Q2 2024 revenue of $13.3 billion
- Pfizer's new hemophilia treatment drug Mataximab's application for market launch in China has been accepted
- The number of infected cases has surged! US FDA approves Pfizer and Modena's updated COVID-19 vaccine
- Pfizer launches drug sales platform directly targeting American patients
- The Phase II clinical trial of Pfizer Ponsegromab in the treatment of cancer cachexia has reached its primary endpoint
- Pfizer and Shangyao Holdings have reached a strategic cooperation to jointly create a new format of high-quality preventive immunization services
-
耐克公司上季度销售额不及预期,撤回新财年全年业绩指引。 当地时间10月1日,耐克公司(NYSE:NIKE)发布截至2024年8月31日的2025财年第一财季财务业绩。该季度实现营收116亿美元,不及市场预期,同比下滑 ...
- 覃志辉
- 昨天 19:09
- 支持
- 反对
- 回复
- 收藏
-
10月1日,国内造车新势力纷纷公布2024年9月交付数据。 据蔚来汽车公告,2024年9月交付汽车21,181辆,同比增长35.4%。截至2024年9月的三个月,交付了汽车61,855辆,同比增长11.6%。截至2024年9月30日,全年 ...
- hzhik
- 前天 19:12
- 支持
- 反对
- 回复
- 收藏
-
纳斯达克中国金龙指数收涨4.94%,热门中概股大涨,哔哩哔哩涨超10%。
- 3215779
- 6 小时前
- 支持
- 反对
- 回复
- 收藏
-
据央视新闻,当地时间9月30日,美国国家运输安全委员会表示,超过40家外国航司正在使用的波音737飞机的方向陀控制系统可能有潜在安全风险。 美国家运输安全委员会透露,该部门已获悉有两家外国运营商在201 ...
- shenhancz
- 前天 10:22
- 支持
- 反对
- 回复
- 收藏